ArticleCell chemical biology2022
Lighting the way to host-directed immunotherapeutics.
Sarah van Tol, Adam Hage, Ricardo Rajsbaum
Open access · greenAbstract readComment
In one paragraphArticle in Cell chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
3 authors at 2 institutions in 1 country.
Sarah van TolDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: savantol@utmb.edu.
Adam HageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: arhage@utmb.edu.
Ricardo RajsbaumCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, USA. Electronic address: ricardo.rajsbaum@rutgers.edu.
The University of Texas Medical Branch at Galveston · USRutgers New Jersey Medical School
Funding
Research Project 3: Role of Posttranslational Protein Modifications in the Pathogenesis of Ebola Virus DiseaseP01AI150585 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER, GARCIA-BLANCO, MARIANO A. · 2021 to 2025
$11.3MRegulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1MEMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1MBiodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0MThe Role of the Host Ubiquitin System in Promoting SARS-CoV-2 Replication and PathogenesisR01AI166668 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2021 to 2025
$2.6MThe Role of TRIM6 and Ubiquitin in Influenza Virus-Induced PathologyR01AI155466 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Ricardo Rajsbaum · 2021 to 2026
$2.5MNIAID NIH HHS P01 AI150585NIAID NIH HHS R01 AI134907NIAID NIH HHS R01 AI155466NIAID NIH HHS R01 AI166668NIAID NIH HHS T32 AI007526NIAID NIH HHS T32 AI060549
6 · The paper itselfAbstract
Developing broad-spectrum, host-directed antiviral therapeutics can be adapted to combat emerging viruses. In this issue of Cell Chemical Biology, Maarifi and colleagues implement a Nano luciferase reporter-based protein complementation assay to screen for small molecules and identify Gilteritinib, which enhances interferon induction and antagonizes virus replication.
Indexed as
Antiviral AgentsVirus ReplicationImmunotherapyAntiviral Agents
Identifiers
PMID35868235
PMCPMC9548442
OpenAlexW4286512376
What OpenQuestion holds
Textmetadata
Read underepoch 390